NCT03298984 2023-11-15Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).Sumitomo Pharma America, Inc.Phase 1 Completed32 enrolled 15 charts